Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
ipo
22
×
life sciences
22
×
national blog main
biotech
boston blog main
national top stories
boston top stories
san francisco blog main
new york blog main
san francisco top stories
texas blog main
texas top stories
new york top stories
san diego blog main
san diego top stories
boulder/denver blog main
boulder/denver top stories
cancer
detroit blog main
detroit top stories
fda
national
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
wisconsin blog main
wisconsin top stories
indiana blog main
indiana top stories
clinical trials
startups
deals
venture capital
eli lilly
novartis
biogen
celgene
crispr
investing
What
bio
roundup
ipo
medicines
new
life
science
cancer
company
drugs
medicine
million
pharmaceutical
public
therapeutics
week
biotech
companies
developing
firms
moves
raised
research
san
way
years
antonio
big
biotechs
black
car
ceo
covid
crispr
deal
debut
diamond’s
drug
fda
gene
Language
unset
Current search:
ipo
×
" life sciences "
×
@xconomy.com
4 years ago
Lyra Therapeutics IPO Raises $56M for Tests of Tech for Runny Noses
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com
4 years ago
Schrödinger Sets Course for IPO to Support Growing Internal Pipeline
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
4 years ago
San Antonio to Honor Regenerative Medicine Pioneer Stephen Badylak
@xconomy.com
4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
5 years ago
San Antonio Wound-Care Company Eyes (Another) Initial Public Offering
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More
@xconomy.com
5 years ago
Synthorx Files for IPO to Advance Enhanced Cytokine Drugs
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
5 years ago
Six Life Science Firms Close Q3 with an IPO, More Are on the Way
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
@xconomy.com
5 years ago
IPO Wave Rolls On as Five Life Science Firms Haul in $651M
@xconomy.com
6 years ago
OncoNano, Maker of Tumor Imaging Technology, Raises $11.7 Million